bioAffinity Technologies, Inc. develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other lung diseases using flow cytometry and AI-driven automated analysis. Its first commercial test, CyPath Lung, analyzes cell populations in sputum to identify malignancy. Tests are performed by its CAP-accredited, CLIA-certified subsidiary PPLS. The company also develops companion diagnostics for asthma and COPD, and conducts cancer therapeutic research through its subsidiary OncoSelect Therapeutics, LLC.
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-16 | 2025-12-31 | 0001493152-26-010143 | EDGAR | 74K words |
| 2025-03-31 | 2024-12-31 | 0001641172-25-001840 | EDGAR | 73K words |
| 2024-04-01 | 2023-12-31 | 0001493152-24-012358 | EDGAR | 73K words |
| 2023-03-31 | 2022-12-31 | 0001493152-23-010186 | EDGAR | 33K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-07 | 2026-06-30 | 0001493152-26-036619 | EDGAR | 25K words |
| 2025-11-14 | 2025-09-30 | 0001493152-25-023405 | EDGAR | 27K words |
| 2025-08-14 | 2025-06-30 | 0001641172-25-024163 | EDGAR | 27K words |
| 2025-05-15 | 2025-03-31 | 0001641172-25-010787 | EDGAR | 22K words |
| 2024-11-14 | 2024-09-30 | 0001493152-24-045954 | EDGAR | 26K words |
| 2024-08-14 | 2024-06-30 | 0001493152-24-031943 | EDGAR | 24K words |
| 2024-05-15 | 2024-03-31 | 0001493152-24-019615 | EDGAR | 20K words |
| 2023-11-14 | 2023-09-30 | 0001493152-23-040986 | EDGAR | 27K words |
| 2023-08-14 | 2023-06-30 | 0001493152-23-028453 | EDGAR | 18K words |
| 2023-05-15 | 2023-03-31 | 0001493152-23-017083 | EDGAR | 13K words |
| 2022-11-14 | 2022-09-30 | 0001493152-22-032248 | EDGAR | 21K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-30 | 0001493152-26-045034 | EDGAR | 1K words |
| 2026-09-22 | 0001493152-26-043654 | EDGAR | 1K words |
| 2026-09-17 | 0001493152-26-043052 | EDGAR | 1K words |
| 2026-09-11 | 0001493152-26-042304 | EDGAR | 0K words |
| 2026-09-09 | 0001493152-26-041894 | EDGAR | 1K words |
| 2026-09-03 | 0001493152-26-041387 | EDGAR | 1K words |
| 2026-09-01 | 0001493152-26-041020 | EDGAR | 1K words |
| 2026-08-20 | 0001493152-26-039375 | EDGAR | 1K words |
| 2026-08-18 | 0001493152-26-038897 | EDGAR | 1K words |
| 2026-08-14 | 0001493152-26-038437 | EDGAR | 1K words |
163 total filings indexed. 138 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001712762 |
| Ticker | BIAF |
| Exchange | Nasdaq |
| SIC | 8731: Services-Commercial Physical & Biological Research |
| Incorporated | DE |
| Headquarters | San Antonio, Texas |
| Website | https://www.bioaffinitytech.com |
| Listed | 2022-09-01 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/BIAF (~200 tokens, structured JSON with cryptographic provenance)